BiondVax Announces Third Quarter 2016 Financial Results and Update

STATEMENTS OF COMPREHENSIVE INCOME

Convenience translation

(Note 2)

Year ended

December 31,

Three months ended

September 30,

Nine months ended

September 30,

Nine months

ended

September 30,

2015

2015

2015

2016

2016

Audited

Unaudited

Unaudited

N I S

U.S. dollars

(In thousands, except per share data)

Operating expenses:

Research and development, net of participations

7,906

1,247

2,421

5,032

5,962

1,586

Marketing, general and administrative

3,397

966

1,049

2,216

2,819

750

Total operating expenses

11,303

2,213

3,470

7,248

8,781

2,336

Operating loss

11,303

2,213

3,470

7,248

8,781

2,336

Financial income

1,118

1,540

10

651

59

16

Financial expense

(24)

(5)

(291)

(20)

(491)

(131)

Financial  income (expenses) due to revaluations of options

10

812

1,395

(315)

2,466

656

Total finance income , net

1,104

2,347

1,114

316

2,034

541

Net loss (income)                                          

10,199

(134)

2,356

6,932

6,747

1,795

Other comprehensive loss (income):

Items to be reclassified to profit or loss in subsequent periods:

Gain (loss) from available-for-sale financial assets

(5)

(2)

1

(5)

(4)

(1)

Total comprehensive loss (income)

10,204

(132)

2,355

6,937

6,751

1,796

Basic and diluted net loss per share (NIS)

0.10

(0.00)

0.02

0.07

0.05

0.01

Weighted average number of shares outstanding used to compute basic and diluted loss per share

105,522,642

135,097,367

135,097,367

95,519,426

135,097,367

135,097,367